Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus nedaplatin bronchial artery perfusion for stage IIIB non-small cell lung cancer
ChiCTR2000035359Phase 4Recruiting
- Sponsor
- Jianyang People's Hospital
- Start
- Aug 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel and nedaplatin in non-small cell lung cancer (NSCLC), sponsored by Jianyang People's Hospital. Primary endpoints: Adverse event and Serious adverse event. Started Aug 2020; status: recruiting.
02
Drugs
paclitaxelnedaplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000035359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035359.